C. Siafarikas, Georgios Karamanakos, K. Makrilakis, Anastasios Tsolakidis, Konstantinos Mathioudakis, Stavros Liatis
OBJECTIVES The aim of this study was to investigate the prevalence and incidence of medication-treated diabetes mellitus and the evolving patterns of glucose-lowering treatments, the year before and, during the first two years of the COVID-19 pandemic. METHODS Data from the Greek electronic prescription database were analyzed for the years 2019, 2020, and 2021. The study population included individuals with active social security numbers. Prevalence and incidence rates were calculated based on the dispensing of glucose-lowering medications, according to their unique ATC (anatomical therapeutic chemical) code. RESULTS The study population comprised 10,289,140 individuals in 2019, 10,630,726 in 2020, and 11,246,136 in 2021. Diabetes prevalence rates were 8.06%, 6.89%, and 7.91%, and incidence rates were 16.8/1000, 8.6/1000, and 13.4/1000 individuals, respectively. Metformin was the most prescribed medication, and newer classes, like SGLT-2 inhibitors and GLP-1 receptor agonists exhibited increasing trends. CONCLUSIONS The study identified a decrease in medication-prescribed diabetes prevalence and incidence during the initial year of the COVID-19 pandemic, attributed to healthcare access restrictions. Subsequently, figures returned close to baseline levels. Glucose-lowering medication trends reflected adherence to local and international guidelines, with metformin as the cornerstone, and increasing preference for newer classes such as GLP-1 receptor agonists and SGLT-2 inhibitors.
{"title":"Prevalence and incidence of medication-treated diabetes and pattern of glucose-lowering treatment during the COVID-19 pandemic: real-world data from the electronic Greek prescription database.","authors":"C. Siafarikas, Georgios Karamanakos, K. Makrilakis, Anastasios Tsolakidis, Konstantinos Mathioudakis, Stavros Liatis","doi":"10.1055/a-2307-4631","DOIUrl":"https://doi.org/10.1055/a-2307-4631","url":null,"abstract":"OBJECTIVES\u0000The aim of this study was to investigate the prevalence and incidence of medication-treated diabetes mellitus and the evolving patterns of glucose-lowering treatments, the year before and, during the first two years of the COVID-19 pandemic.\u0000\u0000\u0000METHODS\u0000Data from the Greek electronic prescription database were analyzed for the years 2019, 2020, and 2021. The study population included individuals with active social security numbers. Prevalence and incidence rates were calculated based on the dispensing of glucose-lowering medications, according to their unique ATC (anatomical therapeutic chemical) code.\u0000\u0000\u0000RESULTS\u0000The study population comprised 10,289,140 individuals in 2019, 10,630,726 in 2020, and 11,246,136 in 2021. Diabetes prevalence rates were 8.06%, 6.89%, and 7.91%, and incidence rates were 16.8/1000, 8.6/1000, and 13.4/1000 individuals, respectively. Metformin was the most prescribed medication, and newer classes, like SGLT-2 inhibitors and GLP-1 receptor agonists exhibited increasing trends.\u0000\u0000\u0000CONCLUSIONS\u0000The study identified a decrease in medication-prescribed diabetes prevalence and incidence during the initial year of the COVID-19 pandemic, attributed to healthcare access restrictions. Subsequently, figures returned close to baseline levels. Glucose-lowering medication trends reflected adherence to local and international guidelines, with metformin as the cornerstone, and increasing preference for newer classes such as GLP-1 receptor agonists and SGLT-2 inhibitors.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"15 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140696631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martin Holder, Thomas Kapellen, Ralph Ziegler, J. Bürger-Büsing, Thomas Danne, Axel Dost, Reinhard W. Holl, P.-M. Holterhus, B. Karges, Olga Kordonouri, Karin Lange, Susanne Müller, K. Raile, Roland Schweizer, Simone von Sengbusch, Rainer Stachow, Verena Wagner, Susanna Wiegand, Andreas Neu
G. Dorneles, Ellen Algeri, Gerhard Lauterbach, Marcelo Pereira, Brigida Fernandes
BACKGROUND To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide treatment in overweight or obese patients without type 2 diabetes. METHODS Randomized clinical trials that accessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from Pubmed, EMBASE, and Lilacs up to November 2023. Risk of bias was assessed with RoB 2.0, and certainty of evidence (CoE) with GRADE. We conducted a random-effects meta-analysis. RESULTS We included ten publications with 22.155 patients. Semaglutide decreased relative body weight (MD: -11.80; 95%CI: -13.53 to -10.07; CoE: High), absolute body weight (MD: -11.58; 95%CI: -13.25 to -9.90; CoE: High) and BMI (MD: -4.15; 95%CI: -4.85 to -3.45; CoE: High). Semaglutide also increased the proportion of patients who achieved 5%, 10% and 15% of weight loss ([weight loss ≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss ≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss ≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]). Semaglutide leads to small risk to adverse events (RR: 1.03; 95%CI: 1 to 1.06; CoE: High), no difference in the serious adverse events (RR: 1.07; 95%CI: 0.70 - 1.62; CoE: Low), but increases in the risk to discontinued treatment (RR: 2.03; 95%CI: 1.87 - 2.20; CoE: High) and gastrointestinal adverse events (RR: 3.26; 95%CI: 1.99 - 5.34; CoE: Moderate). CONCLUSION This up-to-date systematic review highlights that once-weekly semaglutide treatment resulted in clinically important weight loss, becoming a promising adjuvant therapy to treat obesity.
{"title":"Efficacy and safety of once-weekly subcutaneous semaglutide in adults with overweight or obesity: systematic review with meta-analysis.","authors":"G. Dorneles, Ellen Algeri, Gerhard Lauterbach, Marcelo Pereira, Brigida Fernandes","doi":"10.1055/a-2303-8558","DOIUrl":"https://doi.org/10.1055/a-2303-8558","url":null,"abstract":"BACKGROUND\u0000To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide treatment in overweight or obese patients without type 2 diabetes.\u0000\u0000\u0000METHODS\u0000Randomized clinical trials that accessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from Pubmed, EMBASE, and Lilacs up to November 2023. Risk of bias was assessed with RoB 2.0, and certainty of evidence (CoE) with GRADE. We conducted a random-effects meta-analysis.\u0000\u0000\u0000RESULTS\u0000We included ten publications with 22.155 patients. Semaglutide decreased relative body weight (MD: -11.80; 95%CI: -13.53 to -10.07; CoE: High), absolute body weight (MD: -11.58; 95%CI: -13.25 to -9.90; CoE: High) and BMI (MD: -4.15; 95%CI: -4.85 to -3.45; CoE: High). Semaglutide also increased the proportion of patients who achieved 5%, 10% and 15% of weight loss ([weight loss ≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss ≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss ≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]). Semaglutide leads to small risk to adverse events (RR: 1.03; 95%CI: 1 to 1.06; CoE: High), no difference in the serious adverse events (RR: 1.07; 95%CI: 0.70 - 1.62; CoE: Low), but increases in the risk to discontinued treatment (RR: 2.03; 95%CI: 1.87 - 2.20; CoE: High) and gastrointestinal adverse events (RR: 3.26; 95%CI: 1.99 - 5.34; CoE: Moderate).\u0000\u0000\u0000CONCLUSION\u0000This up-to-date systematic review highlights that once-weekly semaglutide treatment resulted in clinically important weight loss, becoming a promising adjuvant therapy to treat obesity.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140717328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rüdiger Landgraf, J. Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
{"title":"Therapy of Type 2 Diabetes.","authors":"Rüdiger Landgraf, J. Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel","doi":"10.1055/a-2166-6755","DOIUrl":"https://doi.org/10.1055/a-2166-6755","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"2010 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140718543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaoyang Su, Wenting Chen, Yidan Fu, Bian Wu, Fugang Mao, Yan Zhao, Qiuping Yang, Danfeng Lan
Diabetic peripheral neuropathy impacts patient quality of life. Increased Mer tyrosine kinase expression has been demonstrated in such patients, yet its mechanism remains unclear. This study established type 2 diabetes mellitus and diabetic peripheral neuropathy models in Sprague Dawley rats via low-dose streptozotocin and a high-fat diet. Mer tyrosine kinase-specific inhibitors were administered by gavage once daily for 2 weeks. Sciatic nerve conduction velocity and nerve structure were measured. The levels of Mer tyrosine kinase, nuclear factor kappa-light-chain-enhancer of activated B cells, tumor necrosis factor-alpha, interleukin-1 beta, and relevant biochemical indexes were detected. The study revealed Mer tyrosine kinase upregulation in type 2 diabetes mellitus and more so in diabetic peripheral neuropathy groups. Inhibiting Mer tyrosine kinase led to reduced nerve conduction velocity and further deterioration of sciatic nerve structure, as evidenced by structural morphology. Concurrently, serum levels of total cholesterol, glycated hemoglobin, and triglyceride significantly rose. Moreover, nuclear factor kappa-light-chain-enhancer of activated B cells levels increased in both serum and nerve tissue, alongside a significant rise in tumor necrosis factor-alpha and interleukin-1 beta expressions. Mer tyrosine kinase was found to bind to inhibitor of kappa B kinase beta in Schwann cells, establishing inhibitor of kappa B kinase beta as a precursor to nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Mer tyrosine kinase exacerbates neuropathy, indicating its protective role in diabetic peripheral neuropathy by suppressing the nuclear factor kappa-light-chain-enhancer of activated B cells pathway, highlighting a potential new target for its diagnosis and treatment.
糖尿病周围神经病变影响患者的生活质量。研究表明，此类患者体内的 Mer 酪氨酸激酶表达增加，但其机制仍不清楚。本研究通过低剂量链脲佐菌素和高脂饮食在 Sprague Dawley 大鼠中建立了 2 型糖尿病和糖尿病周围神经病变模型。Mer 酪氨酸激酶特异性抑制剂每天灌胃一次，持续 2 周。测量坐骨神经传导速度和神经结构。检测了Mer酪氨酸激酶、活化B细胞核因子卡巴轻链增强因子、肿瘤坏死因子α、白细胞介素-1β的水平以及相关生化指标。研究发现，Mer酪氨酸激酶在2型糖尿病中上调，在糖尿病周围神经病变组中上调更为明显。抑制 Mer 酪氨酸激酶会导致神经传导速度降低，坐骨神经结构形态进一步恶化。与此同时，血清总胆固醇、糖化血红蛋白和甘油三酯的水平显著上升。此外，血清和神经组织中活化 B 细胞的核因子卡巴轻链增强因子的水平都有所上升，肿瘤坏死因子-α 和白细胞介素-1β 的表达也显著增加。研究发现，Mer酪氨酸激酶与许旺细胞中的卡巴B激酶β抑制剂结合，从而确定卡巴B激酶β抑制剂是激活活化B细胞的核因子卡巴轻链增强子的前体。抑制 Mer 酪氨酸激酶会加剧神经病变，这表明它通过抑制核因子卡巴轻链-活化 B 细胞增强子通路在糖尿病周围神经病变中发挥保护作用，为诊断和治疗糖尿病周围神经病变提供了一个潜在的新靶点。
{"title":"Protective role of MerTK in diabetic peripheral neuropathy via inhibition of the NF-κb signaling pathway.","authors":"Xiaoyang Su, Wenting Chen, Yidan Fu, Bian Wu, Fugang Mao, Yan Zhao, Qiuping Yang, Danfeng Lan","doi":"10.1055/a-2301-3970","DOIUrl":"https://doi.org/10.1055/a-2301-3970","url":null,"abstract":"Diabetic peripheral neuropathy impacts patient quality of life. Increased Mer tyrosine kinase expression has been demonstrated in such patients, yet its mechanism remains unclear. This study established type 2 diabetes mellitus and diabetic peripheral neuropathy models in Sprague Dawley rats via low-dose streptozotocin and a high-fat diet. Mer tyrosine kinase-specific inhibitors were administered by gavage once daily for 2 weeks. Sciatic nerve conduction velocity and nerve structure were measured. The levels of Mer tyrosine kinase, nuclear factor kappa-light-chain-enhancer of activated B cells, tumor necrosis factor-alpha, interleukin-1 beta, and relevant biochemical indexes were detected. The study revealed Mer tyrosine kinase upregulation in type 2 diabetes mellitus and more so in diabetic peripheral neuropathy groups. Inhibiting Mer tyrosine kinase led to reduced nerve conduction velocity and further deterioration of sciatic nerve structure, as evidenced by structural morphology. Concurrently, serum levels of total cholesterol, glycated hemoglobin, and triglyceride significantly rose. Moreover, nuclear factor kappa-light-chain-enhancer of activated B cells levels increased in both serum and nerve tissue, alongside a significant rise in tumor necrosis factor-alpha and interleukin-1 beta expressions. Mer tyrosine kinase was found to bind to inhibitor of kappa B kinase beta in Schwann cells, establishing inhibitor of kappa B kinase beta as a precursor to nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Mer tyrosine kinase exacerbates neuropathy, indicating its protective role in diabetic peripheral neuropathy by suppressing the nuclear factor kappa-light-chain-enhancer of activated B cells pathway, highlighting a potential new target for its diagnosis and treatment.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"188 1‐6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140730901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cushing's Syndrome (CS) is a rare disease due to chronic endogenous cortisol secretion. In the last years, new acquisitions enlarged the spectrum of differential diagnosis, historically divided into ACTH-dependent and ACTH-independent forms. Moreover, the increased awareness of the detrimental cortisol effects on cardiometabolic health and the risk of cardiovascular events lead to increased diagnosis of mild forms, especially in the context of adrenal incidentalomas. We provide and up-to-date narrative review of the most recent literature regarding the challenges of CS diagnosis. After the description of the diagnostic tools available, we describe the characterization of functional non-neoplastic hypercortisolism (formerly known as pseudo-Cushing state), then we report the subtyping of the different conditions of hypercortisolism: the differential diagnosis of ACTH-dependent forms and the management of adrenal hypercortisolism, with peculiar attention to the new genetic classification of adrenal CS, mild autonomous cortisol secretion and bilateral adrenal adenomas.
{"title":"Subtyping of Cushing's syndrome: a step ahead.","authors":"I. Tizianel, M. Barbot, F. Ceccato","doi":"10.1055/a-2299-5065","DOIUrl":"https://doi.org/10.1055/a-2299-5065","url":null,"abstract":"Cushing's Syndrome (CS) is a rare disease due to chronic endogenous cortisol secretion. In the last years, new acquisitions enlarged the spectrum of differential diagnosis, historically divided into ACTH-dependent and ACTH-independent forms. Moreover, the increased awareness of the detrimental cortisol effects on cardiometabolic health and the risk of cardiovascular events lead to increased diagnosis of mild forms, especially in the context of adrenal incidentalomas. We provide and up-to-date narrative review of the most recent literature regarding the challenges of CS diagnosis. After the description of the diagnostic tools available, we describe the characterization of functional non-neoplastic hypercortisolism (formerly known as pseudo-Cushing state), then we report the subtyping of the different conditions of hypercortisolism: the differential diagnosis of ACTH-dependent forms and the management of adrenal hypercortisolism, with peculiar attention to the new genetic classification of adrenal CS, mild autonomous cortisol secretion and bilateral adrenal adenomas.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"23 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140744020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cognitive dysfunction is an important comorbidity of diabetes. Insulin resistance may play a critical role in diabetes-related cognitive impairment. Echinacoside(ECH), a natural phenylethanoid glycoside, is the active component of anti-diabetes prescriptions in traditional Chinese medicine. Its effect on modulating insulin resistance has been confirmed but modulating neurodegenerative disease still remains to be clarified. Db/db mice, a spontaneous Type 2 diabetes （T2D）mode, were intragastrically administered various doses of ECH or an equivalent volume of saline. Weight, blood glucose, and insulin resistance index were measured. Morris water maze was used to observe the compound effects on cognition. Hippocampal lesions were observed by histochemical analysis. In db/db mice, ECH alleviates diabetes symptoms, memory loss, and hippocampal neuronal damage.Following the step, we found CD44 and phosphorylated tau expression upregulated in diabetic mice. We also found the insulin receptor substrate-1 (IRS1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway dysregulated in diabetic mice. All these changes could be reversed by ECH. Our study provides theoretical support and experimental evidence for the future application of ECH in diabetic cognition dysfunction treatment, promoting the development of traditional medicines.
{"title":"Beneficial effects of Echinacoside on cognitive impairment and diabetes in type 2 diabetic db/db mice.","authors":"Fanglin Qin, Yiming Yan, Ningxi Yang, Yarong Hao","doi":"10.1055/a-2298-4593","DOIUrl":"https://doi.org/10.1055/a-2298-4593","url":null,"abstract":"Cognitive dysfunction is an important comorbidity of diabetes. Insulin resistance may play a critical role in diabetes-related cognitive impairment. Echinacoside(ECH), a natural phenylethanoid glycoside, is the active component of anti-diabetes prescriptions in traditional Chinese medicine. Its effect on modulating insulin resistance has been confirmed but modulating neurodegenerative disease still remains to be clarified. Db/db mice, a spontaneous Type 2 diabetes （T2D）mode, were intragastrically administered various doses of ECH or an equivalent volume of saline. Weight, blood glucose, and insulin resistance index were measured. Morris water maze was used to observe the compound effects on cognition. Hippocampal lesions were observed by histochemical analysis. In db/db mice, ECH alleviates diabetes symptoms, memory loss, and hippocampal neuronal damage.Following the step, we found CD44 and phosphorylated tau expression upregulated in diabetic mice. We also found the insulin receptor substrate-1 (IRS1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway dysregulated in diabetic mice. All these changes could be reversed by ECH. Our study provides theoretical support and experimental evidence for the future application of ECH in diabetic cognition dysfunction treatment, promoting the development of traditional medicines.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"221 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140746716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND Deranged cardiovascular autonomic functions are well-reported complications of diabetes mellitus where chronic hyperglycemia is one of the important factors. But, the role of acute relative hyperglycemia on cardiovascular autonomic functions in healthy subjects is less explored. Hardly any study has reported the effect of acute hyperglycemia on blood pressure variability. Therefore, the present study was planned to study the effect of acute relative hyperglycemia on cardiovascular autonomic functions in healthy young adults. METHODS Beat-to-beat blood pressure and electrocardiogram were recorded for the assessment of heart rate variability and blood pressure variability in forty-two young, healthy subjects during fasting and relative hyperglycemic states. Recorded cardiovascular parameters were analyzed in time and frequency domains. Correlations among analyzed parameters of cardiovascular autonomic variabilities were explored during fasting and relative hyperglycemic state. RESULTS We observed significant alteration of few of the systolic, mean and diastolic blood-pressure-variability-parameters during acute relative hyperglycemia when compared to the fasting state. However, no significant changes were observed in any of the heart-rate-variability parameters. Also, we found novel significant correlations among many of the parameters of cardiovascular autonomic variabilities during fasting and relative hyperglycemic states. CONCLUSIONS Present study concludes that the blood pressure variability is affected significantly during acute relative hyperglycemia in healthy young adults, however, the heart rate variability does not show such changes. Also, many of the parameters of blood pressure variability show significant correlations with heart rate variability and baroreflex sensitivity. We may hypothesize that although the heart rate variability and blood pressure variability assess cardiovascular autonomic functions, blood pressure variability is a better indicator of cardiovascular autonomic effects of acute relative hyperglycemia than heart rate variability.
{"title":"Blood pressure variability is a better associated with acute relative hyperglycemia than the heart rate variability in healthy young adults.","authors":"Kiran Prakash, Navkiran Ranjan, Anita S Malhotra","doi":"10.1055/a-2298-9005","DOIUrl":"https://doi.org/10.1055/a-2298-9005","url":null,"abstract":"BACKGROUND\u0000Deranged cardiovascular autonomic functions are well-reported complications of diabetes mellitus where chronic hyperglycemia is one of the important factors. But, the role of acute relative hyperglycemia on cardiovascular autonomic functions in healthy subjects is less explored. Hardly any study has reported the effect of acute hyperglycemia on blood pressure variability. Therefore, the present study was planned to study the effect of acute relative hyperglycemia on cardiovascular autonomic functions in healthy young adults.\u0000\u0000\u0000METHODS\u0000Beat-to-beat blood pressure and electrocardiogram were recorded for the assessment of heart rate variability and blood pressure variability in forty-two young, healthy subjects during fasting and relative hyperglycemic states. Recorded cardiovascular parameters were analyzed in time and frequency domains. Correlations among analyzed parameters of cardiovascular autonomic variabilities were explored during fasting and relative hyperglycemic state.\u0000\u0000\u0000RESULTS\u0000We observed significant alteration of few of the systolic, mean and diastolic blood-pressure-variability-parameters during acute relative hyperglycemia when compared to the fasting state. However, no significant changes were observed in any of the heart-rate-variability parameters. Also, we found novel significant correlations among many of the parameters of cardiovascular autonomic variabilities during fasting and relative hyperglycemic states.\u0000\u0000\u0000CONCLUSIONS\u0000Present study concludes that the blood pressure variability is affected significantly during acute relative hyperglycemia in healthy young adults, however, the heart rate variability does not show such changes. Also, many of the parameters of blood pressure variability show significant correlations with heart rate variability and baroreflex sensitivity. We may hypothesize that although the heart rate variability and blood pressure variability assess cardiovascular autonomic functions, blood pressure variability is a better indicator of cardiovascular autonomic effects of acute relative hyperglycemia than heart rate variability.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"752 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140749150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-06-03DOI: 10.1055/a-2323-5183
Thomas Skurk, Anja Bosy-Westphal, Arthur Grünerbel, Stefan Kabisch, Winfried Keuthage, Peter Kronsbein, Karsten Müssig, Helmut Nussbaumer, Andreas F H Pfeiffer, Marie-Christine Simon, Astrid Tombek, Katharina S Weber, Diana Rubin
{"title":"Correction: Dietary Recommendations for Persons with Type 2 Diabetes Mellitus.","authors":"Thomas Skurk, Anja Bosy-Westphal, Arthur Grünerbel, Stefan Kabisch, Winfried Keuthage, Peter Kronsbein, Karsten Müssig, Helmut Nussbaumer, Andreas F H Pfeiffer, Marie-Christine Simon, Astrid Tombek, Katharina S Weber, Diana Rubin","doi":"10.1055/a-2323-5183","DOIUrl":"https://doi.org/10.1055/a-2323-5183","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"132 4","pages":"e3"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141238711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-02-06DOI: 10.1055/a-2262-9249
Ante Mandic, Ivana Kraljevic, Tanja Skoric Polovina, Karin Zibar Tomsic, Tina Dusek, Annemarie Balasko, Mirsala Solak, Darko Kastelan
Objective: This study aimed to assess the diagnostic performance of 99mTc-sestamibi SPECT/CT and 18F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT).
Methods: A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either 99mTc-sestamibi SPECT/CT (81 patients) or 18F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, 18F-choline PET/CT was performed after negative or inconclusive findings on 99mTc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings.
Results: The study encompassed 83 patients (70 females, 84.3%) with an average age of 57.2 years (24-80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of 99mTc-sestamibi SPECT/CT was 57% (95% CI 45.3-68.1), while the detection rate of 18F-choline PET/CT was 90.3% (95% CI 74.3-98.0).
Conclusion: The results of our study showed the significant usefulness of 18F-choline PET/CT in patients with negative or inconclusive results of 99mTc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.
{"title":"Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism.","authors":"Ante Mandic, Ivana Kraljevic, Tanja Skoric Polovina, Karin Zibar Tomsic, Tina Dusek, Annemarie Balasko, Mirsala Solak, Darko Kastelan","doi":"10.1055/a-2262-9249","DOIUrl":"10.1055/a-2262-9249","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the diagnostic performance of <sup>99m</sup>Tc-sestamibi SPECT/CT and <sup>18</sup>F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either <sup>99m</sup>Tc-sestamibi SPECT/CT (81 patients) or <sup>18</sup>F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, <sup>18</sup>F-choline PET/CT was performed after negative or inconclusive findings on <sup>99m</sup>Tc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings.</p><p><strong>Results: </strong>The study encompassed 83 patients (70 females, 84.3%) with an average age of 57.2 years (24-80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of <sup>99m</sup>Tc-sestamibi SPECT/CT was 57% (95% CI 45.3-68.1), while the detection rate of <sup>18</sup>F-choline PET/CT was 90.3% (95% CI 74.3-98.0).</p><p><strong>Conclusion: </strong>The results of our study showed the significant usefulness of <sup>18</sup>F-choline PET/CT in patients with negative or inconclusive results of <sup>99m</sup>Tc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"216-220"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139699162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：